Drug intelligence / Profile preview

PLT012R

Development stage: Unknown
Lead developer: Pilatus Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PLT012R is a discovery-stage therapeutic candidate being developed by Pilatus Biosciences for the treatment of lung diseases. It targets CD36 (platelet glycoprotein 4), a key immunometabolic regulator and fatty acid transporter. CD36 is involved in lipid uptake, chronic inflammation, and tissue remodeling. By blocking CD36, PLT012R is designed to reprogram metabolic checkpoints, resolve chronic inflammation, and restore tissue homeostasis in respiratory conditions.

Targets

CD36 (CD36 antigen)

Beyond the preview

Go deeper on PLT012R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLT012R.